Abelcet
(Amphotericin B)ApprovedSmall molecule
This medication is an antifungal injection used to treat serious fungal infections in patients who haven't responded to or cannot tolerate standard amphotericin B treatment. It works by slowing the growth of fungi causing the infection.[2] Abelcet is currently approved and in use across 17 indications[4].[1]
Abelcet is one of 167 small molecule programs targeting Blastomycosis. It is currently in Approved.
17
Indications
37
Total Trials
2
Active Trials
166
Competitors
6
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 17 indications
Competition
Competitive Landscape
255 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Abelcet
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Idamycin
PfizerPhase 3
Novantrone
PfizerPhase 3
Xospata
AstellasPhase 3
Fludara
SanofiPhase 3
Cerubidine
EEastern Cooperative Oncology Group
Phase 3
Vepesid
AAvyxa
Phase 3
Mylotarg
WWyeth-Lederle Vaccines
Phase 3
Vanflyta
Daiichi SankyoPhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cryptococcal Meningitis16 trials
Dexamethasone in Cryptococcal Meningitis
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000776·36 enrolled
Show 13 more trials
A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000639·400 enrolled
High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00885703·168 enrolled
Aspergillosis3 trials
Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation
Unknown status·—·Phase 4·NCT00986713·400 enrolled
Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00001646·10 enrolled
Fungal Infection3 trials
Lung Transplant Recipient2 trials
12 more indications
Neutropenia1 trial
Visceral Leishmaniasis1 trial
Esophagitis1 trial
Infections1 trial
Invasive Fungal Infection1 trial
Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection
Completed·—·Phase 4·NCT06413056·56 enrolled
Meningitis1 trial
Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00145249·143 enrolled
Mucormycosis1 trial
Liposomal Amphotericin B1 trial
Histoplasmosis1 trial
Infection1 trial
Antimicrobial PK in Infants With Suspected or Confirmed Infection
Completed·—··NCT00491426·450 enrolled
Regulatory
FDA Approval Timeline[5]
Jan 1, 1982
FUNGIZONE
NDA NDA050314
Jan 1, 1982
FUNGIZONE
NDA NDA050313
Jan 1, 1982
FUNGIZONE
NDA NDA050341
Nov 20, 1995
ABELCET
NDA NDA050724
Nov 22, 1996
AMPHOTEC
NDA NDA050729
Aug 11, 1997
AMBISOME
NDA NDA050740
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Abelcet drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Amphotericin B. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details